[Press release] Advanced BioDesign and Luxembourg Institute of Health (LIH) join forces to explore new therapeutic strategies for overcoming tumor resistance
Lyon, France, and Luxembourg, July 1, 2020 – Advanced BioDesign, a French biotechnology company specializing in the development of innovative therapies for resistant forms of cancer, and the Luxembourg Institute of Health (LIH), a public biomedical research institute, announce today a partnership to embark on a collaborative research program.
Large Scale COVID-19 testing - This Summer, say #AAAH
The Large Scale Testing COVID-19, developed by Research Luxembourg’s COVID-19 Task Force and led by the Luxembourg Institute of Health is ongoing and will continue until 28 July 2020.. Residents and cross-border workers are still encouraged to participate voluntarily and Say #AAAH.
Research Scientist - YJK0620
The Scientist will work on setting up PersonalizedFunctional drug Profiling Laboratory in Luxembourg. Personalized functional profiling (PFP) is an approachto generate personalized treatment choices for cancer patients. He/she willmainly work on drug profiling using cancer patient’s biopsy to identifypersonalized treatment choice for the patient
Postdoctoral Fellow: Gut microbiome and mucosal barrier in multiple sclerosis - MD0620
We are looking for a talented candidate to apply for a MarieSkłodowska-Curie Actions (MSCA) Individual postdoctoral fellowship 2020. The interested candidate willsubmit an MSCA fellowship jointly with the‘Ecoimmunology & Microbiome Group’ headed by Prof. Mahesh S. Desai. Theresearch project will focus on the interactions between diet, the gutmicrobiome and colonic mucus in a neurodegenerative disease multiple sclerosis(MS). The project is based on the published work (Desai et al., Cell, 2016;Martens…Desai, Nature Reviews Microbiology, 2018) on the same topic andinvolves gnotobiotic mouse models, synthetic microbial communities, MS patientcohorts and key international collaborations in Europe, USA and Japan. Thepostdoc will participate in an exciting research program in an internationalresearch team with prior success with the MSCA applications. Scientific andprofessional guidance will be provided to submit the application for apostdoctoral fellowship that, if successful, could be initiated between spring2021 to early 2022. A 'bridge funding’ option may be available to start earlierin 2020 before the outcome of the fellowship application.
[Press release] Renewed hope for treatment of pain and depression
Researchers at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) developed LIH383, a novel molecule that binds to and blocks a previously unknown opioid receptor in the brain, thereby modulating the levels of opioid peptides produced in the central nervous system (CNS) and potentiating their natural painkilling and antidepressant properties. Opioid peptides are small proteins that act as neuromodulators by interacting with four ‘classical’ opioid receptors on the surface of CNS cells, playing a key role in mediating pain relief but also emotions such as euphoria, anxiety, stress and depression.
25 June 2020 09:00 AM
WEBINAR: Lecture series Infection & Immunity: "Ageing immunity may exacerbate COVID-19"- Prof Arne Akbar
New Full Professorship in Immunology & Genetics at LCSB and LIH for Dirk Brenner
Starting on 15 June, Prof. Dirk Brenner is appointed as joint Professor in Immunology & Genetics at both the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg and the Luxembourg Institute of Health (LIH). This new position will reinforce the already very dynamic immunology research in Luxembourg and develop synergies between the two institutions.